BMND8
MCID: BNM022
MIFTS: 43

Bone Mineral Density Quantitative Trait Locus 8 (BMND8)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 8

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 8:

Name: Bone Mineral Density Quantitative Trait Locus 8 57
Osteoporosis 57 72
Osteoporosis, Susceptibility to 57
Bmnd8 57

Classifications:



External Ids:

OMIM 57 611739
UMLS 72 C0029456

Summaries for Bone Mineral Density Quantitative Trait Locus 8

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 8, also known as osteoporosis, is related to osteoporosis and osteoporosis, juvenile, and has symptoms including tremor, angina pectoris and back pain. An important gene associated with Bone Mineral Density Quantitative Trait Locus 8 is BMND8 (Bone Mineral Density Quantiative Trait Locus 8). The drugs Linagliptin and Magnesium oxide have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate.

More information from OMIM: 611739

Related Diseases for Bone Mineral Density Quantitative Trait Locus 8

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1037)
# Related Disease Score Top Affiliating Genes
1 osteoporosis 13.2
2 osteoporosis, juvenile 12.9
3 osteoporosis-pseudoglioma syndrome 12.8
4 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.6
5 glucocorticoid-induced osteoporosis 12.6
6 juvenile primary osteoporosis 12.6
7 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.5
8 osteoporosis and oculocutaneous hypopigmentation syndrome 12.5
9 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.3
10 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.2
11 dominant hypophosphatemia with nephrolithiasis or osteoporosis 12.2
12 bone mineral density quantitative trait locus 15 12.2
13 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.2
14 hajdu-cheney syndrome 12.1
15 cutis laxa osteoporosis 12.1
16 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 12.1
17 lrp5-related primary osteoporosis 12.1
18 bone mineral density quantitative trait locus 18 12.0
19 acroosteolysis dominant type 12.0
20 bone mineral density quantitative trait locus 16 11.8
21 premature ovarian failure 1 11.6
22 aromatase deficiency 11.6
23 bone mineral density quantitative trait locus 12 11.6
24 bone disease 11.6
25 werner syndrome 11.6
26 syndromic x-linked intellectual disability snyder type 11.6
27 lysinuric protein intolerance 11.5
28 mental retardation, x-linked, syndromic, snyder-robinson type 11.5
29 geroderma osteodysplasticum 11.5
30 hyperparathyroidism 11.5
31 rickets 11.5
32 premature aging syndrome, okamoto type 11.4
33 cerebrotendinous xanthomatosis 11.4
34 acth-secreting pituitary adenoma 11.4
35 cholangitis, primary sclerosing 11.4
36 spondyloocular syndrome 11.4
37 cleidocranial dysplasia 11.4
38 anorexia nervosa 11.4
39 celiac disease 1 11.4
40 systemic mastocytosis 11.4
41 osteopetrosis 11.3
42 hypogonadotropic hypogonadism 11.3
43 graves' disease 11.3
44 severe congenital neutropenia 11.3
45 turner syndrome 11.3
46 pituitary adenoma 4, acth-secreting 11.3
47 homocystinuria 11.3
48 exudative vitreoretinopathy 11.3
49 spinal disease 11.3
50 cleft palate, isolated 11.3

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 8:



Diseases related to Bone Mineral Density Quantitative Trait Locus 8

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 8

Clinical features from OMIM:

611739

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 8:


tremor, angina pectoris, back pain, sciatica, equilibration disorder, muscle cramp, pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 8

Drugs for Bone Mineral Density Quantitative Trait Locus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 647)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Magnesium oxide Approved Phase 4 1309-48-4 14792
3
Dinoprostone Approved Phase 4 363-24-6 5280360
4
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
5
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
9
Tibolone Approved, Investigational Phase 4 5630-53-5
10
Atorvastatin Approved Phase 4 134523-00-5 60823
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Etanercept Approved, Investigational Phase 4 185243-69-0
13
Pamidronate Approved Phase 4 40391-99-9 4674
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Montelukast Approved Phase 4 158966-92-8 5281040
16
Adalimumab Approved Phase 4 331731-18-1 16219006
17
Norethindrone Approved Phase 4 68-22-4 6230
18
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
19
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
20
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
21
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
22
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
23
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
24
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
25
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
26
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
27
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
28
Gliclazide Approved Phase 4 21187-98-4 3475
29
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
30
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
31
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
32
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
33
Ribavirin Approved Phase 4 36791-04-5 37542
34
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
35
Liraglutide Approved Phase 4 204656-20-2 44147092
36
Azathioprine Approved Phase 4 446-86-6 2265
37
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
38
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
39
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
40
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
41
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
42
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
43
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
44
Morphine Approved, Investigational Phase 4 57-27-2 5288826
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
47
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
48
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
49
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
50
Sodium citrate Approved, Investigational Phase 4 68-04-2

Interventional clinical trials:

(show top 50) (show all 2034)
# Name Status NCT ID Phase Drugs
1 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
2 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
3 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
4 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
5 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
6 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
7 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
8 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
9 A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures Unknown status NCT02148848 Phase 4 Risedronate
10 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
11 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
12 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
13 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
14 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
15 Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
16 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
17 Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol. Unknown status NCT01908556 Phase 4 Letrozole
18 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
19 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
20 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
21 A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy Unknown status NCT02322099 Phase 4 Alendronate;Placebo;Tenofovir disoproxil
22 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
23 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
24 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
25 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
26 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
27 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
28 Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis Completed NCT02416271 Phase 4 Teriparatide;Alendronate;Placebo-Oral;Placebo-SC
29 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
30 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
31 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
32 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
33 A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis Completed NCT02948881 Phase 4 ibandronate
34 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
35 Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis Completed NCT00532545 Phase 4 Teriparatide
36 EVA: Evista Alendronate Comparison Completed NCT00035971 Phase 4 raloxifene HCI and alendronate Na
37 A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo Completed NCT00532246 Phase 4 raloxifene;Placebo
38 Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
39 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
40 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
41 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
42 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
43 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
44 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
45 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)
46 Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study Completed NCT00371956 Phase 4 raloxifene;placebo
47 Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis Completed NCT00632216 Phase 4 Risedronate Sodium
48 A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates Completed NCT01732770 Phase 4 Zoledronic Acid;Placebo to Denosumab;Placebo to Zoledronic Acid
49 Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures Completed NCT01709110 Phase 4 Teriparatide;Risedronate;Placebo;Calcium;Vitamin D
50 Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis Completed NCT01753856 Phase 4 Teriparatide;Denosumab;Demeclocycline;Tetracycline;Calcium Supplement;Vitamin D

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 8

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 8

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 8

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 8:

41
Bone, Breast, Prostate, Testes, Kidney, Bone Marrow, Liver

Publications for Bone Mineral Density Quantitative Trait Locus 8

Articles related to Bone Mineral Density Quantitative Trait Locus 8:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Linkage to chromosome 11p12 in two Maltese families with a highly penetrant form of osteoporosis. 38 8
17377523 2007
2
Racial differences in skeletal fragility but not osteoarthritis among women and men with cerebral palsy. 38
31417943 2019
3
The therapeutic effect of secretome from human umbilical cord-derived mesenchymal stem cells in age-related osteoporosis. 38
30977425 2019
4
An insight into the paradigms of osteoporosis: From genetics to biomechanics. 38
31372373 2019
5
Experiences of striving to maintain daily life among women with osteoporosis. 38
31349764 2019
6
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. 38
30665323 2019
7
Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility. 38
30909788 2019
8
Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease. 38
30336748 2019
9
Fracture prediction, imaging and screening in osteoporosis. 38
31189982 2019
10
Mendelian bone fragility disorders. 38
31039433 2019
11
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. 38
30748011 2019
12
A novel quantitative method for estimating bone mineral density using B-mode ultrasound and radiofrequency signals-a pilot study on patients with rheumatoid arthritis. 38
31410123 2019
13
Mendelian randomization in the bone field. 38
30321669 2019
14
SP1-stimulated miR-545-3p inhibits osteogenesis via targeting LRP5-activated Wnt/beta-catenin signaling. 38
31327495 2019
15
Assessment of finite element models for prediction of osteoporotic fracture. 38
31151004 2019
16
Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways. 38
31323222 2019
17
Integrated pathological cell fishing and network pharmacology approach to investigate main active components of Er-Xian decotion for treating osteoporosis. 38
31136804 2019
18
Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. 38
30955181 2019
19
Eldecalcitol, an active vitamin D analog, effectively prevents cyclophosphamide-induced osteoporosis in rats. 38
31410111 2019
20
Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. 38
31106446 2019
21
Chocolate and chocolate constituents influence bone health and osteoporosis risk. 38
31029926 2019
22
Predictors of Nephrolithiasis, Osteoporosis, and Mortality in Primary Hyperparathyroidism. 38
30916764 2019
23
The genetic architecture of osteoporosis and fracture risk. 38
30980960 2019
24
Letter to the Editor: "Two-Thirds of All Fractures Are Not Attributable to Osteoporosis and Advancing Age: Implication for Fracture Prevention". 38
31116397 2019
25
Response to Letter to the Editor: "Two-Thirds of All Fractures Are Not Attributable to Osteoporosis and Advancing Age: Implication for Fracture Prevention". 38
31116398 2019
26
circRNA_0006393 promotes osteogenesis in glucocorticoid‑induced osteoporosis by sponging miR‑145‑5p and upregulating FOXO1. 38
31322188 2019
27
Insight into the possible role of miR-214 in primary osteoporosis via osterix. 38
31056782 2019
28
Comprehensive circular RNA profiling reveals circ_0002060 as a potential diagnostic biomarkers for osteoporosis. 38
31056800 2019
29
Calcium Metabolic Disorders in Pregnancy: Primary Hyperparathyroidism, Pregnancy-Induced Osteoporosis, and Vitamin D Deficiency in Pregnancy. 38
31345528 2019
30
Pulsed vibro-acoustic method for assessment of osteoporosis & osteopenia: A feasibility study on human subjects. 38
31125891 2019
31
An update on therapies for the treatment of diabetes-induced osteoporosis. 38
31079501 2019
32
Strong Bones, Strong Body. 38
31378294 2019
33
[Arthroplasty in patients with osteoporosis]. 38
31428808 2019
34
[Osteoporosis-more newsworthy than ever!] 38
31410592 2019
35
MMP-1 gene polymorphism in osteoporosis. 38
31389576 2019
36
Gene therapy counteracts bone loss in osteoporosis. 38
31384036 2019
37
Correction to: Osteoporosis: Treat-to-Target. 38
31414397 2019
38
[Treatment of osteoporosis is getting more personal]. 38
31416100 2019
39
[Osteoporosis-epidemiology and quality of care]. 38
31139964 2019
40
Editorial Commentary: Aging and Rotator Cuff Tears. 38
31395164 2019
41
[Hounsfield units as a measure of bone density-applications in spine surgery]. 38
31053924 2019
42
Exendin-4 enhances proliferation of senescent osteoblasts through activation of the IGF-1/IGF-1R signaling pathway. 38
31256933 2019
43
[Establishment of fracture liaison services in Germany]. 38
31414147 2019
44
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. 38
31069862 2019
45
Bone mineral density and serum osteocalcin levels in patients with gout. 38
30004299 2019
46
Elucidating the role of size of hydroxyl apatite particles toward the development of competent antiosteoporotic bioceramic materials: In vitro and in vivo studies. 38
30924267 2019
47
The major causes and risk factors of total and cause-specific mortality during 5.4-year follow-up: the Shanghai Changfeng Study. 38
31372866 2019
48
Is vitamin-D supplementation not useful in patients at risk of fractures and falls? 38
31389272 2019
49
Daily intake of polyamine-rich Saccharomyces cerevisiae S631 prevents osteoclastic activation and bone loss in ovariectomized mice. 38
31275725 2019
50
Stimulatory effects of platycodin D on osteoblast differentiation. 38
30887567 2019

Variations for Bone Mineral Density Quantitative Trait Locus 8

Expression for Bone Mineral Density Quantitative Trait Locus 8

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 8.

Pathways for Bone Mineral Density Quantitative Trait Locus 8

GO Terms for Bone Mineral Density Quantitative Trait Locus 8

Sources for Bone Mineral Density Quantitative Trait Locus 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....